Most cited papers from Virginia Mason Memorial

Virginia Mason Memorial

What are the most cited papers from Virginia Mason Memorial?

The most cited paper from Virginia Mason Memorial is "Phenotypic Heterogeneity of Genomic Disorders and Rare Copy-Number Variants" (Santhosh Girirajan et al., 2012), with 645 citations. Next come "Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial" (342) and "Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State" (287).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 6 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Phenotypic Heterogeneity of Genomic Disorders and Rare Copy-Number Variants Santhosh Girirajan et al. · New England Journal of Medicine Open access	12 Sep 2012	645
2	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial Peter Hillmen et al. · The Lancet	15 Apr 2015	342
3	Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State Erica M. Lokken et al. · American Journal of Obstetrics and Gynecology Open access	26 Jan 2021	287
4	Investigation ofNRXN1deletions: Clinical and molecular characterization Mindy Preston Dabell et al. · American Journal of Medical Genetics Part A Open access	12 Mar 2013	112
5	Higher severe acute respiratory syndrome coronavirus 2 infection rate in pregnant patients Erica M. Lokken et al. · American Journal of Obstetrics and Gynecology Open access	16 Feb 2021	109
6	Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes Sheri Skerget et al. · Nature Genetics Open access129 authors	19 Aug 2024	94
7	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) Peter Hillmen, Tadeusz Robak, Ann M. Janssens et al. · Blood	15 Nov 2013	85
8	Dietary Pattern Influences Breast Cancer Prognosis in Women Without Hot Flashes: The Women's Healthy Eating and Living Trial Ellen B. Gold, John P. Pierce, Loki Natarajan et al. · Journal of Clinical Oncology Open access	16 Dec 2008	83
9	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma Tycel Jovelle Phillips, Paul M. Barr, Steven I. Park et al. · Investigational New Drugs Open access	22 Aug 2018	78
10	Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma Nicholas Di Bella, Raymond Taetle, Kathryn S. Kolibaba et al. · Blood	20 Nov 2009	77
11	Reducing Variability in the Infant Sepsis Evaluation (REVISE): A National Quality Initiative Eric Biondi, Russell J. McCulloh, Vincent S. Staggs et al. · PEDIATRICS	21 Aug 2019	67
12	A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma Sumanta Kumar Pal, Andres Forero‐Torres, John A. Thompson et al. · Cancer Open access	9 Jan 2019	67
13	ERBB2 Amplifications in Esophageal Adenocarcinoma Peter S. Dahlberg, Blake A. Jacobson, Ganesh Dahal et al. · The Annals of Thoracic Surgery	Nov 2004	65
14	Disruptive variants of CSDE1 associate with autism and interfere with neuronal development and synaptic transmission Hui Guo et al. · Science Advances Open access	6 Sep 2019	51
15	Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases Costantine Albany, Lawrence H. Einhorn, Lawrence E. Garbo et al. · The Oncologist Open access	8 Dec 2017	50
16	Clinical features in patients with pulmonary embolism at a community hospital: analysis of 4 years of data Navin Bajaj, Andrew L. Bozarth, Juan Guillot et al. · Journal of Thrombosis and Thrombolysis	16 May 2013	48
17	A Comprehensive Strategy for Accurate Mutation Detection of the Highly Homologous PMS2 Jianli Li, Hongzheng Dai, Yanming Feng et al. · Journal of Molecular Diagnostics Open access	27 Aug 2015	46
18	Genetic red flags: clues to thinking genetically in primary care practice Alison J. Whelan, Susie Ball, Lyle G. Best et al. · Primary Care Clinics in Office Practice	Sep 2004	37
19	Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study Steven E. Coutre, John Paul Leonard, Richard R. Furman et al. · Blood	16 Nov 2012	36
20	The double lumen: a pathognomonic angiographic sign of arterial dissection? Allan J. Drapkin · Neuroradiology	10 Mar 2000	31
21	Dealing with prognostic uncertainty: the role of prognostic models and websites for patients with advanced cancer David Hui, John P Maxwell, Carlos Eduardo Paiva · Current Opinion in Supportive and Palliative Care Open access	15 Sep 2019	30
22	Implementation of a New Kiosk Technology for Blood Pressure Management in a Family Medicine Clinic: from the WWAMI Region Practice and Research Network Chia-Fang Chung, Sean A. Munson, Matthew Thompson et al. · The Journal of the American Board of Family Medicine Open access	Sep 2016	25
23	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Stephan Stilgenbauer, Franck Morschhauser, Clemens‐Martin Wendtner et al. · Blood	2 Dec 2016	24
24	Perceived Symptom Experience in Head and Neck Cancer Patients with Lymphedema Jie Fu Deng, Sheila Hedden Ridner, Russell L. Rothman et al. · Journal of Palliative Medicine	12 Sep 2016	23
25	Increased Aripiprazole Concentrations in an HIV-Positive Male Concurrently Taking Duloxetine, Darunavir, and Ritonavir Gregory L Aung, John G. O’Brien, Pamela G Tien et al. · Annals of Pharmacotherapy	26 Oct 2010	22
26	Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study Vicky E. Jones, Kristi J. McIntyre, Devchand Paul et al. · The Oncologist Open access	4 Mar 2019	21
27	Tooth damage in captive orcas (Orcinus orca) John S. Jett, Ingrid Natasha Visser, Jeffrey Ventre et al. · Archives of Oral Biology	30 Sep 2017	21
28	Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Sven de Vos, Richard R. Furman, Jacqueline C. Barrientos et al. · Blood	15 Nov 2013	20
29	A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia Richard R. Furman, Sven de Vos, John Paul Leonard et al. · Blood	15 Nov 2013	20
30	Genetic and phenotypic spectrum in the NONO ‐associated syndromic disorder Franziska Roessler et al. · American Journal of Medical Genetics Part A Open access	25 Nov 2022	19
31	Advanced Practice Pharmacists: a retrospective evaluation of the efficacy and cost of ClinicaL Pharmacist PractitionErs managing ambulatory Medicare patients in North Carolina (APPLE-NC) Michèle M. Kislan, Adam T. Bernstein, Loretta R. Fearrington et al. · BMC Health Services Research Open access	21 Oct 2016	19
32	The effects of asymmetric directional microphone fittings on acceptance of background noise Jong S. Kim, Melinda Freyaldenhoven Bryan · International Journal of Audiology	18 Mar 2011	19
33	A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma Tracy Murray Stewart, Daniel D. Von Hoff, Michael L. Fitzgerald et al. · Cancer Chemotherapy and Pharmacology Open access	19 Nov 2020	18
34	Obstetrical Opportunities: Will Pharmacy Ever Realize Them? Darryl Ragland, GERALD G. BRIGGS, Magdalena Wasik et al. · Annals of Pharmacotherapy	31 Jan 2012	18
35	Refinement of the Region for Split Hand/Foot Malformation 5 on 2q31.1 Aaron P. Theisen et al. · Molecular Syndromology Open access	2010	17
36	Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation Steven E. Coutre et al. · Blood	15 Nov 2013	16
37	Internal iliac artery ligation Frank Le Cocq · American Journal of Obstetrics and Gynecology	Jun 1966	16
38	Preliminary results from the LUX‐Dx insertable cardiac monitor remote programming and performance (LUX‐Dx PERFORM) study Craig Stolen, Jonathan Z. Rosman, Harish Manyam et al. · Clinical Cardiology Open access	8 Oct 2022	15
39	Tumefactive demyelination and glioblastoma: a rare collision lesion Shanu Faerch Roemer, Bernd W. Scheithauer, Georgios Varnavas et al. · Clinical Neuropathology	Jul 2011	15
40	Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer John Wayne Smith, Svetislava J. Vukelja, Anthony D. Hoffman et al. · Clinical Breast Cancer Open access	7 Aug 2015	15
41	Update on the Antimicrobial Management of Foot Infections in Patients With Diabetes Gregory T. Matsuura, Neil L. Barg · Clinical Diabetes	Apr 2013	14
42	Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial for the NRG Oncology, Michael J. Seider, Stephanie L. Pugh et al. · Annals of Nuclear Medicine Open access	9 Aug 2018	13
43	Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study Nathan Hale Fowler, Sven de Vos, Marshall T. Schreeder et al. · Blood	16 Nov 2012	13
44	Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results Sven de Vos, Nina D. Wagner‐Johnston, Steven E. Coutre et al. · Blood	6 Dec 2014	13
45	Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Jacqueline C. Barrientos, Steven E. Coutre, Sven de Vos et al. · Blood	6 Dec 2014	13
46	Measles Immunity Among Community Hospital Employees Peter M. Houck, Gay Scott-Johnson, Lylanne Krebs · Infection Control and Hospital Epidemiology	Nov 1991	13
47	Evaluation of a Multidisciplinary, Simulation-based Hospital Residency Program PHILIP E. YOUNG, Janis Burke · Clinical Simulation in Nursing	20 Nov 2009	12
48	Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Gilles Salles, Thomas E. Boyd, Franck Morschhauser et al. · Blood	3 Dec 2015	11
49	Antimicrobial stewardship through a one health lens Marisa D’Angeli, Joe B. Baker, Douglas Ruben Call et al. · International Journal of Health Governance	13 Aug 2016	11
50	Implementation of a fully remote randomized clinical trial with cardiac monitoring Jacob J. Mayfield et al. · Communications Medicine Open access154 authors	20 Dec 2021	10

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.